ArticleProceedings of the National Academy of Sciences of the United States of America1993
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 200 citations in OpenAlex.
- Vascular Disruption Therapy as a New Strategy for Cancer Treatment.International journal of molecular sciences · 2025Review
- Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.Oncotarget · 2016Article
- MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome.Cancer research · 2016Article
- Article
- Anticancer strategies involving the vasculature.Nature reviews. Clinical oncology · 2009Review
- Antiangiogenic therapy in brain tumors.Expert review of neurotherapeutics · 2008Review
- A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes.BMC genomics · 2008Article
- Radionuclide carriers for targeting of cancer.International journal of nanomedicine · 2008Review
- [Identification of the molecular bases of metastasis for the development of new therapy strategies of metastatic prostate carcinoma].Der Urologe. Ausg. A · 2007Article
- Vascular targeting: recent advances and therapeutic perspectives.Trends in cardiovascular medicine · 2006Review
- Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.Journal of neuro-oncology · 2003Review
- Therapeutic inhibition of angiogenesis.Molecular biotechnology · 2003Review
- Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.Journal of neuro-oncology · 2001Article
- Antitumor effect of the idiotypic cascade induced by an antibody encapsulated in poly(d,l-lactide-co-glycolide) microspheres.Japanese journal of cancer research : Gann · 2001Article
- Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.British journal of cancer · 2000Article
- Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy.British journal of cancer · 1999Article
- [Anti-angiogenesis: a new approach to tumor therapy?].Medizinische Klinik (Munich, Germany : 1983) · 1999Article
- Review
- Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antibody-based therapy of solid tumors has met with limited success, chiefly because solid tumors are relatively impermeable to macromolecules. This problem could be circumvented by attacking the readily accessible endothelial cells of the tumor vascular bed. We have developed a model to test this "vascular targeting" approach in which cytokine gene transfection of the tumor cells causes them to induce an experimental marker selectively on tumor vascular endothelium. An anti-tumor endothelial cell immunotoxin caused complete occlusion of the tumor vasculature and dramatic regressions of large solid tumors. By contrast, a conventional anti-tumor cell immunotoxin of equivalent in vitro potency produced only minor, transient antitumor effects but, when combined, the two immunotoxins induced permanent complete remissions in over half of the animals. These experiments indicate that immunotoxins directed against recently described markers on vascular endothelial cells in human tumors could provide a general treatment for solid tumors in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.